Yescarta-话题@MedSci - 梅斯（MedSci）

#Yescarta#

7篇内容 | 1104人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1615170, encodeId=c8c416151e002, content=<a href='/topic/show?id=c22b189565e' target=_blank style='color:#2F92EE;'>#Yescarta#</a>, objectTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, objectType=article, longId=723516, objectId=7576e23516c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7576e23516c3, replyNumber=0, likeNumber=92, createdTime=2022-04-06, rootId=0, userName=小华子, userId=e5a919584515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7576e23516c3, moduleTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7576e23516c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615169, encodeId=7c61161516943, content=<a href='/topic/show?id=c22b189565e' target=_blank style='color:#2F92EE;'>#Yescarta#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=58, createdTime=2021-01-26, rootId=0, userName=小华子, userId=e5a919584515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615168, encodeId=6d001615168be, content=<a href='/topic/show?id=c22b189565e' target=_blank style='color:#2F92EE;'>#Yescarta#</a>, objectTitle=4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露, objectType=article, longId=187885, objectId=d23418e8852c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d23418e8852c, replyNumber=0, likeNumber=107, createdTime=2020-02-14, rootId=0, userName=小华子, userId=e5a919584515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d23418e8852c, moduleTitle=4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d23418e8852c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615167, encodeId=77fd161516e91, content=<a href='/topic/show?id=c22b189565e' target=_blank style='color:#2F92EE;'>#Yescarta#</a>, objectTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, objectType=article, longId=184904, objectId=574418490463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574418490463, replyNumber=0, likeNumber=78, createdTime=2019-12-19, rootId=0, userName=小华子, userId=e5a919584515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574418490463, moduleTitle=百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=574418490463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615166, encodeId=e1091615166c1, content=<a href='/topic/show?id=c22b189565e' target=_blank style='color:#2F92EE;'>#Yescarta#</a>, objectTitle=第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据, objectType=article, longId=182556, objectId=c322182556d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c322182556d8, replyNumber=0, likeNumber=76, createdTime=2019-11-09, rootId=0, userName=小华子, userId=e5a919584515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c322182556d8, moduleTitle=第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c322182556d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615165, encodeId=46c71615165be, content=<a href='/topic/show?id=c22b189565e' target=_blank style='color:#2F92EE;'>#Yescarta#</a>, objectTitle=加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤, objectType=article, longId=160891, objectId=16d216089137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d216089137, replyNumber=0, likeNumber=80, createdTime=2019-02-25, rootId=0, userName=小华子, userId=e5a919584515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d216089137, moduleTitle=加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=16d216089137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1615164, encodeId=f65c161516449, content=<a href='/topic/show?id=c22b189565e' target=_blank style='color:#2F92EE;'>#Yescarta#</a>, objectTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, objectType=article, longId=149577, objectId=a4e21495e77d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4e21495e77d, replyNumber=0, likeNumber=76, createdTime=2018-09-27, rootId=0, userName=小华子, userId=e5a919584515, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4e21495e77d, moduleTitle=【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a4e21495e77d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Yescarta

2020-05-29

小华子 (审核中...)

前往app查看评论内容

#Yescarta#

CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤

2022-04-06

小华子 (审核中...)

前往app查看评论内容

#Yescarta#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-01-26

小华子 (审核中...)

前往app查看评论内容

#Yescarta#

4.56亿美元，吉利德CAR-T疗法Yescarta2019年销售业绩披露

2020-02-14

小华子 (审核中...)

前往app查看评论内容

#Yescarta#

百时美施贵宝控告吉利德的CAR-T细胞疗法Yescarta专利侵权案胜诉，将赢得7.52亿美元的赔偿

2019-12-19

小华子 (审核中...)

前往app查看评论内容

#Yescarta#

第61届ASH：Kite将展示Yescarta治疗多种血液肿瘤的全新数据

2019-11-09

小华子 (审核中...)

前往app查看评论内容

#Yescarta#

加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤

2019-02-25

小华子 (审核中...)

前往app查看评论内容

#Yescarta#

【2018 CSCO】黄慧强教授：CAR-T产品Yescarta在复发/难治NHL的治疗中处于领先地位

2018-09-27

科室
- - 订阅+
  - 更多科室
工具
服务